- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04300803
Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL
August 26, 2020 updated by: MorphoSys AG
An Expanded Access Protocol to Provide Intermediate Access to Tafasitamab (MOR208) for the Combination Treatment With Lenalidomide to Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Expanded Access Program (EAP) to provide Tafasitamab (MOR208) to eligible patients with relapsed or refractory Diffuse Large B Cell Lymphoma.
Access to MorphoSys´ EAP can be requested by contacting the respective CRO Clinigen (tafasitamab@clinigengroup.com).
Study Overview
Status
Approved for marketing
Conditions
Detailed Description
This program is intended to provide access to patients with relapsed and/or refractory DLBCL who had at least one prior anti-CD20 containing regimen.
Patients with primary refractory disease and double/triple hit status are also eligible.
Patients considering this access program should have no other therapeutic option, and are not eligible for other clinical trials.
The expanded access program (MOR208N001) is currently available in the United States only.
Study Type
Expanded Access
Expanded Access Type
- Treatment IND/Protocol
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Description
Major Inclusion Criteria :
- Age ≥ 18 years
- Patient able to provide written informed consent
- Histologically-confirmed diagnosis of DLBCL, including transformation from an earlier diagnosis of indolent lymphoma.
- Patients must have relapsed and/or refractory DLBCL, including primary refractory disease and double/triple hit status, after at least 1 prior anti-CD20 containing regimen.
- Patients with a serious, life-threatening illness in which conventional therapies have failed, are unsuitable and/or are unavailable and participation in ongoing relevant clinical trials is not feasible.
Major Exclusion Criteria:
- Patients who have other histological type of lymphoma, e.g. indolent Non-Hodgkin lymphoma (NHL), Primary mediastinal B-cell lymphoma (PMBL) or Burkitt Lymphoma
- Patients who are not willing/able to take venous thromboembolic event prophylaxis during the entire treatment period with lenalidomide
Patients with:
- Known active bacterial and viral and fungal infections
- Serology of chronic active viral Hepatitis B and/or C-Hepatitis
- Known seropositivity for or history of active viral infection with human immunodeficiency virus (HIV)
- Patients who are unable to participate in the lenalidomide REMS program
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
March 5, 2020
First Submitted That Met QC Criteria
March 5, 2020
First Posted (Actual)
March 9, 2020
Study Record Updates
Last Update Posted (Actual)
August 28, 2020
Last Update Submitted That Met QC Criteria
August 26, 2020
Last Verified
May 1, 2020
More Information
Terms related to this study
Other Study ID Numbers
- MOR208N001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on DLBCL
-
Fondazione Italiana Linfomi - ETSJanssen-Cilag S.p.A.Recruiting
-
The First Affiliated Hospital with Nanjing Medical...RecruitingEBV-Positive DLBCL, NosChina
-
The First Affiliated Hospital with Nanjing Medical...RecruitingDLBCL | Untreated | MYC Gene RearrangementChina
-
Memorial Sloan Kettering Cancer CenterActinium PharmaceuticalsRecruitingDiffuse Large B-cell Lymphoma | B-ALL | DLBCL | DLBCL, Nos Genetic Subtypes | B ALL | Dlbcl-Ci | DLBCL Unclassifiable | DLBCL Activated B-Cell Type | DLBCL Germinal Center B-Cell Type | HGBL | HGBL, NosUnited States
-
Acerta Pharma BVTerminatedDLBCL | Richter SyndromeUnited Kingdom, United States
-
The Lymphoma Academic Research OrganisationCHU de NancyCompleted
-
Memorial Sloan Kettering Cancer CenterSanofi; Columbia University; Medical College of Wisconsin; University of Rochester and other collaboratorsActive, not recruitingDiffuse Large B-cell Lymphoma (DLBCL) | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)United States
-
Beijing InnoCare Pharma Tech Co., Ltd.Recruiting
-
University Hospital, SaarlandCompletedDLBCL | Old Age; DebilityGermany
Clinical Trials on Tafasitamab, 12 mg/kg. 4 week cycles: weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), loading dose Cycle 1, day 4. Cycle 4 onwards day 1, day 15 until disease progression
-
Amsterdam UMC, location VUmcNot yet recruitingMultiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory
-
Memorial Sloan Kettering Cancer CenterAstellas Pharma US, Inc.CompletedEGFR-Mutant Lung CancerUnited States
-
Memorial Sloan Kettering Cancer CenterTufts Medical Center; Lahey ClinicCompleted
-
Memorial Sloan Kettering Cancer CenterBristol-Myers SquibbCompletedLeukemia | Acute Lymphoblastic LeukemiaUnited States